- Company
- Repotrectinib receives orphan drug designation in Korea
- by Eo, Yun-Ho May 17, 2024 05:47am
- , The &160;ROS1-targeted lung cancer drug repotrectinib received an orphan drug designation in Korea. The Ministry of Food and Drug Safety (MFDS) announced the designation in a recent announcement. Specifically, the indications repotrectinib received orphan drug designation for are as follows: ▲ treatment for patients with ROS1-posit
- Company
- Chinese Pharmas show presence at BIO Korea 2024
- by Moon, sung-ho May 16, 2024 05:48am
- Chinese pharmaceutical companies are starting to enter the domestic pharmaceutical and biotechnology market in earnest. This was the main observation made by the Korean industry at ‘BIO Korea 2024,’ cohosted by the Ministry of Health and Welfare and the Korea Health Industry Development Institute. The activities of major Chinese phar
- Company
- Xcopri’s cumulative revenue surpasses KRW 1 trillion
- by Chon, Seung-Hyun May 16, 2024 05:48am
- Xcopri, SK Biopharmaceutical's new epilepsy drug, is continuing to show strong growth in the US market. Since its launch, sales have continued to rise every quarter, with cumulative sales exceeding KRW 600 billion. When including the revenue it had collected by licensing-out Xcopri’s technology, the company has secured more than KRW 1 trillion
- Company
- "Camzyos, reimbursement would benefit gov and patients"
- by Eo, Yun-Ho May 16, 2024 05:48am
- The reason for delayed drug development in a particular disease typically falls into one of two. It’s either low awareness of the disease or challenges to drug development. Despite falling into these two categories, 'Camzyos (mavacamten)' was developed. It is a first-in-class targeted treatment option for obstructive hypertrophic cardi
- Company
- New oral psoriasis drug 'Sotyktu' available in hospitals
- by Eo, Yun-Ho May 14, 2024 05:48am
- An oral psoriasis drug 'Sotyktu' is becoming available for prescription at general hospitals. According to industry sources, BMS Korea’s Sotyktu (deucravacitinib) has passed the drug committee (DC) of hospitals, including Seoul Asan Hospital, Severance Hospital, Konyang University Hospital, Soonchunghyang University Bucheon Hospital, Se
- Company
- Ryvrevant to lead market with Exkivity’s market withdrawal
- by Son, Hyung-Min May 14, 2024 05:48am
- Exkivity, a treatment for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation, is being withdrawn from the market. The highly anticipated oral treatment failed to demonstrate efficacy in a confirmatory clinical trial, leading to its market withdrawal. With no competition, Rybrevant is expected to remain the market leader
- Company
- AbbVie’s Aquipta becomes the first oral CGRP migraine drug
- by Son, Hyung-Min May 13, 2024 05:52am
- For the first time, an oral CGRP drug has been introduced for the treatment of migraine. AbbVie’s Aquipta has shown positive results as a preventive treatment for chronic migraine as well as episodic migraine in patients who have failed up to 4 prior oral preventive treatments. Experts believe that the benefits of being an oral formulation
- Company
- BeiGene reapplies for Tevimbra’s reimb in esophageal cancer
- by Eo, Yun-Ho May 13, 2024 05:52am
- BeiGene is again attempting reimbursement for its immunotherapy, ‘Tevimbra (tislelizumab)’ in Korea. According to industry sources, BeiGene Korea recently submitted an application for the reimbursement of its Tevimbra (tiselizumab) and is waiting for the Health Insurance Review and Assessment Service's Cancer Disease Review Committee’s
- Company
- MM drug Tecvayli can be prescribed in tertiary hospitals
- by Eo, Yun-Ho May 13, 2024 05:52am
- The new multiple myeloma drug ‘Tecvayli’ can now be prescribed in tertiary hospitals in Korea. According to industry sources, Janssen Korea’s multiple myeloma drug Tecvayli (teclistamab) has passed the drug committee (DC) review of top tertiary hospitals in Korea, including Samsung Medical Center, Seoul National University Hospital, Se
- Company
- Pharma companies showcase their R&D achievements
- by Son, Hyung-Min May 13, 2024 05:52am
- Pharmaceutical companies have disclosed the development outcomes of the obesity treatments, which have now become the trending R&D. As obesity treatments of the GLP-1 class, such as those of Novo Nordisk and Lilly, become blockbuster new drugs globally, the development of latecomers is on the rise. Major companies plan to develop the next-
